D.B. Shin

1.2k total citations · 1 hit paper
17 papers, 698 citations indexed

About

D.B. Shin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, D.B. Shin has authored 17 papers receiving a total of 698 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in D.B. Shin's work include Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (8 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). D.B. Shin is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (8 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). D.B. Shin collaborates with scholars based in South Korea, United States and Japan. D.B. Shin's co-authors include Yoon‐Koo Kang, Won Ki Kang, Р. Ш. Хасанов, T. Suarez, Jie Wang, Javier Gutiérrez Santamarı́a, Jianping Xiong, Jingyu Chen, Mikhail Lichinitser and P. McCloud and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

D.B. Shin

15 papers receiving 684 citations

Hit Papers

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as... 2009 2026 2014 2020 2009 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
    2009 582 citations Yoon‐Koo Kang, Won Ki Kang et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D.B. Shin South Korea 6 603 395 269 268 67 17 698
Kirstin Breithaupt Germany 7 509 0.8× 286 0.7× 197 0.7× 260 1.0× 37 0.6× 10 558
M. Wenczl Hungary 6 557 0.9× 423 1.1× 113 0.4× 198 0.7× 63 0.9× 15 705
W. Rodriguez United States 3 376 0.6× 236 0.6× 148 0.6× 182 0.7× 27 0.4× 3 437
Nadine Röthling Germany 8 495 0.8× 311 0.8× 81 0.3× 406 1.5× 45 0.7× 11 658
Keisei Taku Japan 12 349 0.6× 195 0.5× 107 0.4× 223 0.8× 32 0.5× 33 459
Syoichi Fujii Japan 8 280 0.5× 203 0.5× 102 0.4× 195 0.7× 35 0.5× 12 446
Toshiyuki Tanahashi Japan 14 468 0.8× 219 0.6× 235 0.9× 277 1.0× 92 1.4× 52 714
Paula Kareclas United Kingdom 7 395 0.7× 238 0.6× 138 0.5× 236 0.9× 60 0.9× 8 545
S. Giaquinta Italy 10 463 0.8× 483 1.2× 115 0.4× 215 0.8× 67 1.0× 24 670
Junichiro Nasu Japan 10 599 1.0× 348 0.9× 327 1.2× 310 1.2× 51 0.8× 26 784

Countries citing papers authored by D.B. Shin

Since Specialization
Citations

This map shows the geographic impact of D.B. Shin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.B. Shin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.B. Shin more than expected).

Fields of papers citing papers by D.B. Shin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.B. Shin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.B. Shin. The network helps show where D.B. Shin may publish in the future.

Co-authorship network of co-authors of D.B. Shin

This figure shows the co-authorship network connecting the top 25 collaborators of D.B. Shin. A scholar is included among the top collaborators of D.B. Shin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.B. Shin. D.B. Shin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Reck, Martin, Alexander Luft, Igor Bondarenko, et al.. (2019). A phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC. Annals of Oncology. 30. v644–v645. 2 indexed citations
2.
Ahn, Hee Kyung, et al.. (2018). Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer treated with chemotherapy. Annals of Oncology. 29. ix52–ix52. 2 indexed citations
3.
Shin, Dong Wook, Juhee Cho, So Young Kim, et al.. (2016). Attitudes toward participating in Phase I clinical trials: an investigation with patient–family–physician triads. Japanese Journal of Clinical Oncology. 46(12). 1095–1101.
4.
5.
Kang, Yoon‐Koo, Lin Shen, Kun‐Huei Yeh, et al.. (2014). Randomized Phase Ii Study of Capecitabine and Cisplatin with or Without Sorafenib in Patients with Metastatic Gastric Cancer: Stargate Study. Annals of Oncology. 25. iv210–iv210. 16 indexed citations
6.
Shin, Jin Woo, et al.. (2010). The Results of Radiation Therapy with Chemotherapy for Patients with Cervical Cancer and Supraclavicular Lymph Node Involvement. International Journal of Radiation Oncology*Biology*Physics. 78(3). S403–S404.
7.
Kang, Yoon‐Koo, Won Ki Kang, D.B. Shin, et al.. (2009). Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Annals of Oncology. 20(4). 666–673. 582 indexed citations breakdown →
8.
Cho, Eun Young, Sun Young Kyung, So‐Yeon Shim, et al.. (2009). Pemetrexed versus gefitinib versus erlotinib in previously treated non-small cell lung cancer by retrospective analysis. Journal of Clinical Oncology. 27(15_suppl). e19103–e19103. 1 indexed citations
9.
Lee, Seung Hwan, Jennifer Choi, Jae Hwan Oh, et al.. (2008). Chemoradiotherapy Followed by Surgery in Rectal Cancer: Improved Local Control Using a Moderately High Pelvic Radiation Dose. Japanese Journal of Clinical Oncology. 38(2). 112–121. 10 indexed citations
10.
11.
Shin, D.B., et al.. (2007). Randomized phase II trial of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) for advanced gastric cancer. Journal of Clinical Oncology. 25(18_suppl). 4580–4580. 3 indexed citations
12.
Ahn, Jeong Yeal, Soo‐Mee Bang, Pil-Whan Park, et al.. (2007). JAK2V617F Mutation in Korean Patients with Essential Thrombocythemia. Annals of Laboratory Medicine. 27(2). 77–80. 6 indexed citations
13.
Shin, D.B., et al.. (2006). Second-line chemotherapy with mitomycin C and S-1 in patients with advanced gastric cancer. Journal of Clinical Oncology. 24(18_suppl). 14083–14083. 2 indexed citations
14.
Bang, Soo‐Mee, et al.. (2005). Randomized phase II trial of taxanes plus 5-fluorouracil for advanced gastric cancer. Journal of Clinical Oncology. 23(16_suppl). 4149–4149. 2 indexed citations
15.
Bang, Soo‐Mee, et al.. (2005). Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors. Journal of Clinical Oncology. 23(16_suppl). 8100–8100. 2 indexed citations
16.
Bang, Soo‐Mee, et al.. (2004). The changes in quality of life during the palliative chemotherapy for solid cancer. Journal of Clinical Oncology. 22(14_suppl). 8237–8237. 1 indexed citations
17.
Chung, Min, et al.. (2004). Interim analysis from a prospective randomized trial of taxanes plus 5-FU in advanced gastric cancer. Journal of Clinical Oncology. 22(14_suppl). 4193–4193. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kirstin Breithaupt Breakdown of academic impact, for papers by M. Wenczl Breakdown of academic impact, for papers by W. Rodriguez Breakdown of academic impact, for papers by Nadine Röthling Breakdown of academic impact, for papers by Keisei Taku Breakdown of academic impact, for papers by Syoichi Fujii Breakdown of academic impact, for papers by Toshiyuki Tanahashi Breakdown of academic impact, for papers by Paula Kareclas Breakdown of academic impact, for papers by S. Giaquinta Breakdown of academic impact, for papers by Junichiro Nasu
Rankless by CCL
2026